Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Authors
Keywords
Macrodomain, DLBCL, ARTD, PARP, DTX3L, NF-κB, STAT1, STAT3, Chemoresistance, ADP-ribosylation, Antibody drug conjugate, ABC-DLBCL, GCB-DLBCL, BCR, CAR-T cells
Journal
Molecular Cancer
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-12-12
DOI
10.1186/s12943-015-0474-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis.
- (2017) J. D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
- (2015) T. E. Witzig et al. ANNALS OF ONCOLOGY
- Mechanistic overview of ADP-ribosylation reactions
- (2015) Vicky M.-H. Sung BIOCHIMIE
- Evolution: IMiDs to PPMs, revolution in DLBCL?
- (2015) G. S. Nowakowski BLOOD
- CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
- (2015) P. R. Hagner et al. BLOOD
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
- (2015) E. D. Jacobsen et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Digging deep into “dirty” drugs – modulation of the methylation machinery
- (2015) Lisa Pleyer et al. DRUG METABOLISM REVIEWS
- Towards small molecule inhibitors of mono-ADP-ribosyltransferases
- (2015) Torun Ekblad et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis
- (2015) Karen Dybkær et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
- (2015) Grzegorz S. Nowakowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
- (2015) M Pfeifer et al. LEUKEMIA
- IL10 receptor is a novel therapeutic target in DLBCLs
- (2015) W Béguelin et al. LEUKEMIA
- Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
- (2015) L Li et al. LEUKEMIA
- Structural genomic alterations in primary mediastinal large B-cell lymphoma
- (2015) David D. W. Twa et al. LEUKEMIA & LYMPHOMA
- Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma
- (2015) Morihiro Higashi et al. LEUKEMIA & LYMPHOMA
- A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
- (2015) Nina D. Wagner-Johnston et al. LEUKEMIA & LYMPHOMA
- Ibrutinib: from bench side to clinical implications
- (2015) Davide Grisafi et al. MEDICAL ONCOLOGY
- ARTD1 suppresses interleukin 6 expression by repressing MLL1-dependent histone H3 trimethylation
- (2015) Roberta Minotti et al. MOLECULAR AND CELLULAR BIOLOGY
- CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
- (2015) D. S. Mortensen et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
- (2015) Boris Shor et al. MOLECULAR IMMUNOLOGY
- TET1 is a tumor suppressor of hematopoietic malignancy
- (2015) Luisa Cimmino et al. NATURE IMMUNOLOGY
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress
- (2015) Claudia M. Nicolae et al. NUCLEIC ACIDS RESEARCH
- The tumor microenvironment shapes hallmarks of mature B-cell malignancies
- (2015) K H Shain et al. ONCOGENE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma
- (2015) Matthew P. Walker et al. Science Signaling
- Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma
- (2015) Emmanuel Bachy et al. SEMINARS IN HEMATOLOGY
- MYC Alterations in Diffuse Large B-Cell Lymphomas
- (2015) Kennosuke Karube et al. SEMINARS IN HEMATOLOGY
- Cracking the Diverse Biologic Code of Diffuse Large B-Cell Lymphoma
- (2015) Mark Roschewski et al. SEMINARS IN HEMATOLOGY
- The Genetic Landscape of Diffuse Large B-Cell Lymphoma
- (2015) Laura Pasqualucci et al. SEMINARS IN HEMATOLOGY
- B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
- (2015) Ryan M. Young et al. SEMINARS IN HEMATOLOGY
- Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma
- (2015) Neha Mehta-Shah et al. SEMINARS IN HEMATOLOGY
- Emerging Biological Insights and Novel Treatment Strategies in Primary Mediastinal Large B-Cell Lymphoma
- (2015) Kieron Dunleavy et al. SEMINARS IN HEMATOLOGY
- Epigenomic evolution in diffuse large B-cell lymphomas
- (2015) Heng Pan et al. Nature Communications
- HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma
- (2015) Danielle P. Johnson et al. Oncotarget
- Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway
- (2015) Nguyen Dinh Thang et al. Oncotarget
- An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression
- (2015) Baochun Zhang et al. Cell Reports
- FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma
- (2015) Matthew P. Walker et al. Science Signaling
- CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
- (2015) G P Gregory et al. LEUKEMIA
- Recurrent targets of aberrant somatic hypermutation in lymphoma
- (2015) Alireza Hadj Khodabakhshi et al. Oncotarget
- Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
- (2015) Jonathan Feld et al. Oncotarget
- A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
- (2015) Russell T Burke et al. Oncotarget
- Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
- (2015) Vivien Landré et al. Oncotarget
- Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma
- (2015) Scott A. Ezell et al. Oncotarget
- Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
- (2015) Yulia N. Demchenko et al. Oncotarget
- Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
- (2015) Albert A. Antolín et al. Oncotarget
- Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
- (2015) Enrico Derenzini et al. Oncotarget
- Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
- (2014) Min Shi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- PARP inhibitors for anticancer therapy
- (2014) Nicola Curtin BIOCHEMICAL SOCIETY TRANSACTIONS
- Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase
- (2014) J. J. Steinhardt et al. BLOOD
- Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
- (2014) Kieron Dunleavy et al. BLOOD
- Genetic inactivation of TRAF3 in canine and human B-cell lymphoma
- (2014) K. R. Bushell et al. BLOOD
- FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- B to promote survival of human B cells
- (2014) M. van Keimpema et al. BLOOD
- An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup
- (2014) F. C. Chan et al. BLOOD
- Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
- (2014) David D. W. Twa et al. BLOOD
- A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
- (2014) T. Berg et al. BLOOD
- Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients
- (2014) N. F. C. C. de Miranda et al. BLOOD
- Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
- (2014) Tatyana Feldman et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD30 expression inde novodiffuse large B-cell lymphoma: a population-based study from British Columbia
- (2014) Graham W. Slack et al. BRITISH JOURNAL OF HAEMATOLOGY
- MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
- (2014) Anamarija M. Perry et al. BRITISH JOURNAL OF HAEMATOLOGY
- Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer
- (2014) John T. Cunningham et al. CELL
- NF-κB pathways in hematological malignancies
- (2014) Chiara Gasparini et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
- (2014) William D. Bradley et al. CHEMISTRY & BIOLOGY
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
- (2014) Y. Hao et al. CLINICAL CANCER RESEARCH
- PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo
- (2014) M. Rahmani et al. CLINICAL CANCER RESEARCH
- Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
- (2014) S. E. Trabucco et al. CLINICAL CANCER RESEARCH
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
- (2014) A. Stathis et al. EUROPEAN JOURNAL OF CANCER
- Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia
- (2014) Caroline Le Jeune et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma
- (2014) Maria Bach Laursen et al. EXPERIMENTAL HEMATOLOGY
- Pidilizumab in the treatment of diffuse large B-cell lymphoma
- (2014) Locke J Bryan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasms
- (2014) Allison Rosenthal et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
- (2014) Matthew S Davids et al. Future Oncology
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Host STAT2/type I interferon axis controls tumor growth
- (2014) Chanyu Yue et al. INTERNATIONAL JOURNAL OF CANCER
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
- (2014) Michael Crump et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
- (2014) Anas Younes et al. LANCET ONCOLOGY
- Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
- (2014) Umberto Vitolo et al. LANCET ONCOLOGY
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
- (2014) S L Khaw et al. LEUKEMIA
- MicroRNAs in B-cell lymphomas: how a complex biology gets more complex
- (2014) K Musilova et al. LEUKEMIA
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients
- (2014) Joshua Lukenbill et al. LEUKEMIA & LYMPHOMA
- TP53mutations are frequent events in double-hit B-cell lymphomas withMYCandBCL2but notMYCandBCL6translocations
- (2014) Niklas Gebauer et al. LEUKEMIA & LYMPHOMA
- Differential Properties of Transcriptional Complexes Formed by the CoREST Family
- (2014) A. P. Barrios et al. MOLECULAR AND CELLULAR BIOLOGY
- STAT1 Is Not Dominant Negative and Is Capable of Contributing to Gamma Interferon-Dependent Innate Immunity
- (2014) C. Semper et al. MOLECULAR AND CELLULAR BIOLOGY
- DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
- (2014) Samia B Bachmann et al. Molecular Cancer
- Abstract C244: Development of the BET bromodomain inhibitor OTX015.
- (2014) J. K. Noel et al. MOLECULAR CANCER THERAPEUTICS
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
- (2014) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling
- (2014) Ronald Bozeman et al. MOLECULAR CARCINOGENESIS
- Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
- (2014) Jagan R. Muppidi et al. NATURE
- Precision therapy for lymphoma—current state and future directions
- (2014) Andrew M. Intlekofer et al. Nature Reviews Clinical Oncology
- Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
- (2014) Philip P Chamberlain et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells
- (2014) Xin-Yan Pei et al. PLoS One
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
- (2014) Lesley A. Mathews Griner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance
- (2014) Benjamin Bonavida SEMINARS IN ONCOLOGY
- ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen
- (2014) Ying-hui Song et al. TUMOR BIOLOGY
- Double-hit lymphomas: current paradigms and novel treatment approaches
- (2014) K. Dunleavy Hematology-American Society of Hematology Education Program
- Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas
- (2013) Raju K. Pillai et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Accelerated therapeutic progress in diffuse large B cell lymphoma
- (2013) Qingqing Cai et al. ANNALS OF HEMATOLOGY
- Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
- (2013) J. Shortt et al. BLOOD
- The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop
- (2013) J. N. Psathas et al. BLOOD
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
- (2013) J. E. Amengual et al. BLOOD
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF- 1/SMAD5 signaling module
- (2013) D. Jiang et al. BLOOD
- I B- controls the constitutive NF- B target gene network and survival of ABC DLBCL
- (2013) H. Nogai et al. BLOOD
- CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
- (2013) S. Hu et al. BLOOD
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
- (2013) R. D. Morin et al. BLOOD
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial
- (2013) Mathias Witzens-Harig et al. BMC CANCER
- Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
- (2013) K Harada et al. BRITISH JOURNAL OF CANCER
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
- (2013) Julie M. Vose et al. BRITISH JOURNAL OF HAEMATOLOGY
- ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- (2013) Meike Vogler et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
- (2013) Girija Dasmahapatra et al. BRITISH JOURNAL OF HAEMATOLOGY
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas
- (2013) Linfeng Chen et al. CANCER CELL
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation
- (2013) X. Zhang et al. CANCER RESEARCH
- PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains
- (2013) S. Picaud et al. CANCER RESEARCH
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma
- (2013) Matthias Pfeifer et al. CELL CYCLE
- Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma
- (2013) L. Fontan et al. CLINICAL CANCER RESEARCH
- PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
- (2013) K. Walsh et al. CLINICAL CANCER RESEARCH
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2013) V. Ribrag et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Diffuse large B-cell lymphoma
- (2013) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
- (2013) Anouk Emadali et al. EMBO Molecular Medicine
- IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9
- (2013) Holger H H Erb et al. ENDOCRINE-RELATED CANCER
- In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity
- (2013) Malgorzata Szelag et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib
- (2013) Enrico Derenzini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-MycB-cell lymphomain vivo
- (2013) Jennifer R. Devlin et al. FEBS Journal
- Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
- (2013) A. Chiappella et al. HAEMATOLOGICA
- Reprogramming cell death: BCL2 family inhibition in hematological malignancies
- (2013) Lydia Scarfò et al. IMMUNOLOGY LETTERS
- BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN -STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma
- (2013) R. Camicia et al. JOURNAL OF CELL SCIENCE
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
- (2013) Julie M. Vose et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
- (2013) Xin Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA repair genes are selectively mutated in diffuse large B cell lymphomas
- (2013) Noel FCC de Miranda et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Replenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1
- (2013) Sebak Datta et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma
- (2013) Brent D. G. Page et al. JOURNAL OF MEDICINAL CHEMISTRY
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
- (2013) David Cunningham et al. LANCET
- Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
- (2013) C C Bjorklund et al. LEUKEMIA
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
- (2013) M Wang et al. LEUKEMIA
- Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma
- (2013) Chuanbing Zang et al. LEUKEMIA & LYMPHOMA
- Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond
- (2013) Ben-Zion Katz et al. LEUKEMIA & LYMPHOMA
- Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
- (2013) Jennifer R. Brown LEUKEMIA & LYMPHOMA
- Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy
- (2013) Hans Erik Johnsen et al. LEUKEMIA & LYMPHOMA
- Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling
- (2013) Tobias Karlberg et al. MOLECULAR ASPECTS OF MEDICINE
- BH3 Mimetics: Status of the Field and New Developments
- (2013) C. Billard MOLECULAR CANCER THERAPEUTICS
- Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population
- (2013) Dennis E K Tan et al. NATURE GENETICS
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
- (2013) Carol Y Ying et al. NATURE IMMUNOLOGY
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Diffuse large B-cell lymphoma—treatment approaches in the molecular era
- (2013) Mark Roschewski et al. Nature Reviews Clinical Oncology
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Targeting pathological B cell receptor signalling in lymphoid malignancies
- (2013) Ryan M. Young et al. NATURE REVIEWS DRUG DISCOVERY
- Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation
- (2013) Karla L. H. Feijs et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
- (2013) K H Shain et al. ONCOGENE
- Deltex-1 Activates Mitotic Signaling and Proliferation and Increases the Clonogenic and Invasive Potential of U373 and LN18 Glioblastoma Cells and Correlates with Patient Survival
- (2013) Roland M. Huber et al. PLoS One
- A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling
- (2013) Guangzhen Hu et al. PLoS One
- Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation
- (2013) Mayte Suárez-Fariñas et al. PLoS One
- Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?
- (2013) Sylvia Hartmann et al. PLoS One
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- B-cell receptor signaling as a driver of lymphoma development and evolution
- (2013) Carsten U. Niemann et al. SEMINARS IN CANCER BIOLOGY
- Newly Identified Mechanisms in B-Cell Non-Hodgkin Lymphomas Uncovered by Next-Generation Sequencing
- (2013) Ryan D. Morin et al. SEMINARS IN HEMATOLOGY
- Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
- (2013) Robert Z. Orlowski SEMINARS IN ONCOLOGY
- Recognition of Mono-ADP-Ribosylated ARTD10 Substrates by ARTD8 Macrodomains
- (2013) Alexandra H. Forst et al. STRUCTURE
- Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
- (2013) Leandro Cerchietti et al. Expert Review of Hematology
- TYK2–STAT1–BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia
- (2013) Takaomi Sanda et al. Cancer Discovery
- Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
- (2013) T. Clozel et al. Cancer Discovery
- Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
- (2013) L. Cerchietti et al. Hematology-American Society of Hematology Education Program
- Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
- (2013) George W. Small et al. PeerJ
- Beyond DNA Repair: Additional Functions of PARP-1 in Cancer
- (2013) Alice N. Weaver et al. Frontiers in Oncology
- Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology
- (2012) Albert A. Antolín et al. ACS Chemical Biology
- Pathogenesis of Human B Cell Lymphomas
- (2012) Arthur L. Shaffer et al. Annual Review of Immunology
- Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ
- (2012) Paul Warrener et al. APOPTOSIS
- Relapses, treatments and new drugs
- (2012) Nicolas Mounier et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
- (2012) Z. Y. Xu-Monette et al. BLOOD
- Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
- (2012) Z. Y. Xu-Monette et al. BLOOD
- MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation
- (2012) W. Cuccuini et al. BLOOD
- Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
- (2012) M. Gupta et al. BLOOD
- Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas
- (2012) G. D. Victora et al. BLOOD
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
- (2012) Hsiao-Ching Chuang et al. BREAST CANCER RESEARCH AND TREATMENT
- Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma
- (2012) Julio García-Suárez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
- (2012) Ling-Hua Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma
- (2012) Pilar Caro et al. CANCER CELL
- MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
- (2012) Lorena Fontan et al. CANCER CELL
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
- (2012) Stefano Monti et al. CANCER CELL
- Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1
- (2012) Chuanbing Zang et al. CANCER LETTERS
- BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death
- (2012) Chaitali Dutta et al. CANCER RESEARCH
- Unphosphorylated STAT1 Promotes Sarcoma Development through Repressing Expression of Fas and Bad and Conferring Apoptotic Resistance
- (2012) M. A. Zimmerman et al. CANCER RESEARCH
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Interferon/Stat1 Pathway: Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth
- (2012) N. N. Khodarev et al. CLINICAL CANCER RESEARCH
- Dual Inhibition of Canonical and Noncanonical NF- B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
- (2012) C. Fabre et al. CLINICAL CANCER RESEARCH
- RRM–RNA recognition: NMR or crystallography…and new findings
- (2012) Gerrit M Daubner et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Structural insight into the interaction of ADP-ribose with the PARP WWE domains
- (2012) Fahu He et al. FEBS LETTERS
- Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination
- (2012) Z. Wang et al. GENES & DEVELOPMENT
- Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes
- (2012) Suzan Guney et al. GENES CHROMOSOMES & CANCER
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
- (2012) J. A. Barnes et al. HAEMATOLOGICA
- Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study
- (2012) Pier Luigi Zinzani et al. HEMATOLOGICAL ONCOLOGY
- A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology
- (2012) Burkhard Hirsch et al. HISTOPATHOLOGY
- Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer
- (2012) Christina Magkou et al. HISTOPATHOLOGY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Diffuse large B cell lymphoma: molecular targeted therapy
- (2012) Mark Roschewski et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
- (2012) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
- (2012) Pasquale Sansone et al. JOURNAL OF CLINICAL ONCOLOGY
- Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK–Positive Non–Small-Cell Lung Cancer
- (2012) Akihiro Tamiya et al. JOURNAL OF CLINICAL ONCOLOGY
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
- (2012) Ranjana H. Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Ligands for ADP-Ribosyltransferases via Docking-Based Virtual Screening
- (2012) C. David Andersson et al. JOURNAL OF MEDICINAL CHEMISTRY
- The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies
- (2012) Ambrogio Fassina et al. LABORATORY INVESTIGATION
- MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma
- (2012) S-S Wenzel et al. LEUKEMIA
- Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
- (2012) H Tilly et al. LEUKEMIA
- Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma
- (2012) Lucile Couronné et al. LEUKEMIA & LYMPHOMA
- BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8
- (2012) Q. Yan et al. MOLECULAR AND CELLULAR BIOLOGY
- Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
- (2012) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- Inflammasome-Activated Caspase 7 Cleaves PARP1 to Enhance the Expression of a Subset of NF-κB Target Genes
- (2012) Süheda Erener et al. MOLECULAR CELL
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4
- (2012) Jun Cui et al. NATURE IMMUNOLOGY
- Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma
- (2012) A Barbarulo et al. ONCOGENE
- Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
- (2012) Michael J. Kluk et al. PLoS One
- Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model
- (2012) Bhuvanesh Dave et al. PLoS One
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fold of the conserved DTC domain in deltex proteins
- (2012) Josiah Obiero et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- The double-edged sword of Notch signaling in cancer
- (2012) Andrew P. South et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- The PIM kinases in hematological cancers
- (2012) Yesid Alvarado et al. Expert Review of Hematology
- MYC and Aggressive B-cell Lymphomas
- (2011) Graham W. Slack et al. ADVANCES IN ANATOMIC PATHOLOGY
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
- (2011) T. E. Witzig et al. ANNALS OF ONCOLOGY
- HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells
- (2011) Juraj Bodo et al. APOPTOSIS
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
- (2011) I. N. M. Micallef et al. BLOOD
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
- (2011) M. Gupta et al. BLOOD
- The molecular pathogenesis of primary mediastinal large B-cell lymphoma
- (2011) C. Steidl et al. BLOOD
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression
- (2011) S. Kannan et al. BLOOD
- SYK inhibition and response prediction in diffuse large B-cell lymphoma
- (2011) S. Cheng et al. BLOOD
- The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
- (2011) E. Campo et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- STAT3 activation in monocytes accelerates liver cancer progression
- (2011) Wen-Yong Wu et al. BMC CANCER
- Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
- (2011) A Smith et al. BRITISH JOURNAL OF CANCER
- Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
- (2011) Francisco J. Hernandez-Ilizaliturri et al. CANCER
- Autophagy as a therapeutic target in cancer
- (2011) Ning Chen et al. CANCER BIOLOGY & THERAPY
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
- (2011) E. A. Stronach et al. CANCER RESEARCH
- Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
- (2011) T. L. Naylor et al. CANCER RESEARCH
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
- (2011) A. Scuto et al. CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease
- (2011) Krzysztof Sikorski et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies
- (2011) Loic Ysebaert et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma
- (2011) Monica Civallero et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states
- (2011) Tim J. Wigle et al. FEBS LETTERS
- The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3
- (2011) Davide Schiavone et al. FEBS LETTERS
- The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion
- (2011) V. Biberacher et al. HAEMATOLOGICA
- A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
- (2011) W. H. Wilson et al. HAEMATOLOGICA
- High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy
- (2011) T. M. Cardesa-Salzmann et al. HAEMATOLOGICA
- Epidemiology of lymphomas
- (2011) Eve Roman et al. HISTOPATHOLOGY
- The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
- (2011) Catherine Thieblemont et al. JOURNAL OF CLINICAL ONCOLOGY
- High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma
- (2011) Wu ZL et al. Journal of Hematology & Oncology
- Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
- (2011) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma
- (2011) P Ruminy et al. LEUKEMIA
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
- (2011) G S Nowakowski et al. LEUKEMIA
- Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
- (2011) M Gupta et al. LEUKEMIA
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Interleukin-6 plasma levels are modulated by a polymorphism in theNF-κB1gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma
- (2011) Manuela Giachelia et al. LEUKEMIA & LYMPHOMA
- B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome
- (2011) Shaoying Li et al. MODERN PATHOLOGY
- QKI-Mediated Alternative Splicing of the Histone Variant MacroH2A1 Regulates Cancer Cell Proliferation
- (2011) L. Novikov et al. MOLECULAR AND CELLULAR BIOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Inactivating mutations of acetyltransferase genes in B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
- (2011) Christian Steidl et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma
- (2011) R R Singh et al. ONCOGENE
- Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family
- (2011) S. H. Cho et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Malt1-dependent RelB cleavage promotes canonical NF- B activation in lymphocytes and lymphoma cell lines
- (2011) S. Hailfinger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Progress in the Function and Regulation of ADP-Ribosylation
- (2011) M. O. Hottiger et al. Science Signaling
- Molecular pathogenesis of diffuse large B-cell lymphoma
- (2011) Christof Schneider et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification
- (2011) Thomas Tousseyn et al. VIRCHOWS ARCHIV
- Gene Inactivation Promotes Immune Escape In DLBCL
- (2011) Cancer Discovery
- Signal Transduction Inhibitor Therapy for Lymphoma
- (2011) T. E. Witzig et al. Hematology-American Society of Hematology Education Program
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2011) J. W. Friedberg Hematology-American Society of Hematology Education Program
- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- (2010) Matija Snuderl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain
- (2010) Rebecca L. Lamason et al. BIOCHEMISTRY
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review
- (2010) Denise M. Oliansky et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78
- (2010) G. Roue et al. BLOOD
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
- (2010) D. Yecies et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor- B-inducing kinase while activating both canonical and alternative nuclear factor- B pathways
- (2010) L. V. Pham et al. BLOOD
- Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
- (2010) F. Jardin et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma
- (2010) Sonali M. Smith et al. BLOOD CELLS MOLECULES AND DISEASES
- Cooperative Epigenetic Modulation by Cancer Amplicon Genes
- (2010) Lixin Rui et al. CANCER CELL
- BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma
- (2010) Jonathan Mandelbaum et al. CANCER CELL
- A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
- (2010) Leandro C. Cerchietti et al. CANCER CELL
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Epigenetic therapy of lymphoma using histone deacetylase inhibitors
- (2010) Maribel Cotto et al. Clinical & Translational Oncology
- Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2010) Julie Lignon et al. Clinical Lymphoma Myeloma & Leukemia
- Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
- (2010) Takashi Watanabe EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lymphoma stem cells: enough evidence to support their existence?
- (2010) J. A. Martinez-Climent et al. HAEMATOLOGICA
- The intrathymic crossroads of T and NK cell differentiation
- (2010) Roel G. J. Klein Wolterink et al. IMMUNOLOGICAL REVIEWS
- PARP-14 Functions as a Transcriptional Switch for Stat6-dependent Gene Activation
- (2010) Purvi Mehrotra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
- (2010) Leandro C. Cerchietti et al. JOURNAL OF CLINICAL INVESTIGATION
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
- (2010) Jia Ruan et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium
- (2010) Ajay K. Gopal et al. LEUKEMIA & LYMPHOMA
- Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- (2010) Sari Riihijärvi et al. MODERN PATHOLOGY
- NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma
- (2010) Seong-Su Han et al. Molecular Cancer
- Resistance to IFN- -Induced Apoptosis Is Linked to a Loss of STAT2
- (2010) A. L. Romero-Weaver et al. MOLECULAR CANCER RESEARCH
- Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression
- (2010) Wioleta Luszczek et al. MOLECULAR CANCER THERAPEUTICS
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells
- (2010) B. Kloo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting of SMAD5 links microRNA-155 to the TGF- pathway and lymphomagenesis
- (2010) D. Rai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toward a unified nomenclature for mammalian ADP-ribosyltransferases
- (2010) Michael O. Hottiger et al. TRENDS IN BIOCHEMICAL SCIENCES
- p53 post-translational modification: deregulated in tumorigenesis
- (2010) Chao Dai et al. TRENDS IN MOLECULAR MEDICINE
- Oncogenic Activation of NF- B
- (2010) L. M. Staudt Cold Spring Harbor Perspectives in Biology
- PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells
- (2009) S. H. Cho et al. BLOOD
- Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma
- (2009) O. Ritz et al. BLOOD
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
- (2009) N. A. Johnson et al. BLOOD
- Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities
- (2009) A. Mottok et al. BLOOD
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect
- (2009) Sean P Pitroda et al. BMC Medicine
- Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model
- (2009) Shigeo Masuda et al. CANCER SCIENCE
- Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma
- (2009) Suk-young Lee et al. CANCER SCIENCE
- PI3 Kinase Signals BCR-Dependent Mature B Cell Survival
- (2009) Lakshmi Srinivasan et al. CELL
- Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
- (2009) Ji Luo et al. CELL
- Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
- (2009) Y. Terui et al. CLINICAL CANCER RESEARCH
- Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy
- (2009) M. Y. Zhao et al. CLINICAL CANCER RESEARCH
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Lymphocytes in cancer development: Polarization towards pro-tumor immunity
- (2009) Brian Ruffell et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival
- (2009) Paul et al. Frontiers in Bioscience-Landmark
- CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure
- (2009) N. A. Johnson et al. HAEMATOLOGICA
- T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response
- (2009) P. Van Loo et al. HAEMATOLOGICA
- Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling
- (2009) Elena V. Efimova et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Interferon-resistant Daudi Cell Line with a Stat2 Defect Is Resistant to Apoptosis Induced by Chemotherapeutic Agents
- (2009) Ziyun Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells
- (2009) Uta Ferch et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
- Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations
- (2009) N Niitsu et al. LEUKEMIA
- pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation
- (2009) Douglas A. Stewart et al. LEUKEMIA & LYMPHOMA
- Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
- (2009) Claudia Stolz et al. LEUKEMIA & LYMPHOMA
- Protein kinase C-betaII expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab
- (2009) Kritika Chaiwatanatorn et al. LEUKEMIA & LYMPHOMA
- Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP
- (2009) Dilek Dincol et al. MEDICAL ONCOLOGY
- A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro
- (2009) Wai M. Liu et al. MOLECULAR BIOLOGY REPORTS
- BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response
- (2009) Qingsheng Yan et al. MOLECULAR CELL
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
- (2009) Mara Compagno et al. NATURE
- STAT3 inhibition of gluconeogenesis is downregulated by SirT1
- (2009) Yongzhan Nie et al. NATURE CELL BIOLOGY
- A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
- (2009) Leandro C Cerchietti et al. NATURE MEDICINE
- A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation
- (2009) Gyula Timinszky et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- STAT1 Pathway Mediates Amplification of Metastatic Potential and Resistance to Therapy
- (2009) Nikolai N. Khodarev et al. PLoS One
- Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma
- (2009) S. Hailfinger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
- (2009) M. Saito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
- (2009) E. S. Jaffe Hematology-American Society of Hematology Education Program
- SIRT1 Expression is Associated With Poor Prognosis of Diffuse Large B-Cell Lymphoma
- (2008) Kyu Yun Jang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Host immune response in B-cell lymphomas: friend or foe?
- (2008) Przemysław Juszczyński et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling
- (2008) X. Lu et al. BLOOD
- A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
- (2008) L. C. Cerchietti et al. BLOOD
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
- (2008) K. H. Young et al. BLOOD
- Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome
- (2008) B. Chetaille et al. BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Tenets of PTEN Tumor Suppression
- (2008) Leonardo Salmena et al. CELL
- Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression
- (2008) S. H. Olejniczak et al. CLINICAL CANCER RESEARCH
- The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- (2008) M. B. Meads et al. CLINICAL CANCER RESEARCH
- Primary mediastinal large B-cell lymphoma
- (2008) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- STAT 3 as a Target for Cancer Drug Discovery
- (2008) Luca Costantino et al. CURRENT MEDICINAL CHEMISTRY
- R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study
- (2008) A. Martin et al. HAEMATOLOGICA
- MYCtranslocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type
- (2008) S O Yoon et al. HISTOPATHOLOGY
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
- (2008) Wyndham H. Wilson et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel function of STAT1β in B cells: induction of cell death by a mechanism different from that of STAT1α
- (2008) Imen Najjar et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
- (2008) Michael Pfreundschuh et al. LANCET ONCOLOGY
- STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma
- (2008) O Ritz et al. LEUKEMIA
- Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
- (2008) W Klapper et al. LEUKEMIA
- Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers ofin vivoresponse
- (2008) Jane Houldsworth et al. LEUKEMIA & LYMPHOMA
- Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients
- (2008) Aylin Sar et al. LEUKEMIA RESEARCH
- ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
- (2008) Scott Ackler et al. MOLECULAR CANCER THERAPEUTICS
- AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
- (2008) Dana M. Gwinn et al. MOLECULAR CELL
- The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers
- (2008) Zuyao Ni et al. NATURE IMMUNOLOGY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
- (2008) R. R. Weichselbaum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
- (2008) G. Lenz et al. SCIENCE
- Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
- (2008) Gabriella Regis et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma
- (2007) L. T. Lam et al. BLOOD
- Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
- (2007) E. Vellenga et al. BLOOD
- The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
- (2007) Paul et al. Frontiers in Bioscience-Landmark
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started